These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 34384024)
1. Discovery and Toxicological Profiling of Aminopyridines as Orally Bioavailable Selective Inhibitors of PI3-Kinase γ. Bellenie BR; Hall E; Bruce I; Spendiff M; Culshaw A; McDonald S; Ambarkhane A; Chinn C; Thomas M; Rosner E; Bracher M; Nicklin P; Marshall S; Coote J; Cullen E; Tessier C; Wuersch K; Lal A; Wallis G; Hollingworth GJ; Neef J J Med Chem; 2021 Aug; 64(16):12304-12321. PubMed ID: 34384024 [TBL] [Abstract][Full Text] [Related]
2. The discovery and evaluation of 3-amino-2(1H)-pyrazinones as a novel series of selective p38α MAP kinase inhibitors. Raubo P; Evans R; Willis P Bioorg Med Chem Lett; 2020 Sep; 30(18):127412. PubMed ID: 32717614 [TBL] [Abstract][Full Text] [Related]
3. Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines. Lin H; Yamashita DS; Xie R; Zeng J; Wang W; Leber J; Safonov IG; Verma S; Li M; Lafrance L; Venslavsky J; Takata D; Luengo JI; Kahana JA; Zhang S; Robell KA; Levy D; Kumar R; Choudhry AE; Schaber M; Lai Z; Brown BS; Donovan BT; Minthorn EA; Brown KK; Heerding DA Bioorg Med Chem Lett; 2010 Jan; 20(2):684-8. PubMed ID: 20006500 [TBL] [Abstract][Full Text] [Related]
4. Discovery of a novel aminopyrazine series as selective PI3Kα inhibitors. Barlaam B; Cosulich S; Fitzek M; Germain H; Green S; Hanson LL; Harris CS; Hancox U; Hudson K; Lambert-van der Brempt C; Lamorlette M; Magnien F; Ouvry G; Page K; Ruston L; Ward L; Delouvrié B Bioorg Med Chem Lett; 2017 Jul; 27(13):3030-3035. PubMed ID: 28526367 [TBL] [Abstract][Full Text] [Related]
5. Novel Class of Colony-Stimulating Factor 1 Receptor Kinase Inhibitors Based on an Xie Z; Wu B; Liu Y; Ren W; Tong L; Xiang C; Wei A; Gao Y; Zeng L; Xie H; Tang W; Hu Y J Med Chem; 2020 Feb; 63(3):1397-1414. PubMed ID: 31934767 [TBL] [Abstract][Full Text] [Related]
6. The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5- Goldberg FW; Finlay MRV; Ting AKT; Beattie D; Lamont GM; Fallan C; Wrigley GL; Schimpl M; Howard MR; Williamson B; Vazquez-Chantada M; Barratt DG; Davies BR; Cadogan EB; Ramos-Montoya A; Dean E J Med Chem; 2020 Apr; 63(7):3461-3471. PubMed ID: 31851518 [TBL] [Abstract][Full Text] [Related]
7. Discovery of AZD8154, a Dual PI3Kγδ Inhibitor for the Treatment of Asthma. Perry MWD; Björhall K; Bold P; Brűlls M; Börjesson U; Carlsson J; Chang HA; Chen Y; Eriksson A; Fihn BM; Fransson R; Fredlund L; Ge H; Huang H; Karabelas K; Lamm Bergström E; Lever S; Lindmark H; Mogemark M; Nikitidis A; Palmgren AP; Pemberton N; Petersen J; Rodrigo Blomqvist M; Smith RW; Thomas MJ; Ullah V; Tyrchan C; Wennberg T; Westin Eriksson A; Yang W; Zhao S; Öster L J Med Chem; 2021 Jun; 64(12):8053-8075. PubMed ID: 34080862 [TBL] [Abstract][Full Text] [Related]
8. Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors. Ma CC; Zhang CM; Tang LQ; Liu ZP Eur J Med Chem; 2018 May; 151():9-17. PubMed ID: 29601991 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase. Lumeras W; Caturla F; Vidal L; Esteve C; Balagué C; Orellana A; Domínguez M; Roca R; Huerta JM; Godessart N; Vidal B J Med Chem; 2009 Sep; 52(17):5531-45. PubMed ID: 19678708 [TBL] [Abstract][Full Text] [Related]
10. Efficacious, orally bioavailable thrombin inhibitors based on 3-aminopyridinone or 3-aminopyrazinone acetamide peptidomimetic templates. Sanderson PE; Lyle TA; Cutrona KJ; Dyer DL; Dorsey BD; McDonough CM; Naylor-Olsen AM; Chen IW; Chen Z; Cook JJ; Cooper CM; Gardell SJ; Hare TR; Krueger JA; Lewis SD; Lin JH; Lucas BJ; Lyle EA; Lynch JJ; Stranieri MT; Vastag K; Yan Y; Shafer JA; Vacca JP J Med Chem; 1998 Nov; 41(23):4466-74. PubMed ID: 9804686 [TBL] [Abstract][Full Text] [Related]
11. Targeting phosphatidylinositol 3-kinase gamma (PI3Kγ): Discovery and development of its selective inhibitors. Zhu J; Li K; Yu L; Chen Y; Cai Y; Jin J; Hou T Med Res Rev; 2021 May; 41(3):1599-1621. PubMed ID: 33300614 [TBL] [Abstract][Full Text] [Related]
12. Discovery of a highly potent orally bioavailable imidazo-[1, 2-a]pyrazine Aurora inhibitor. Yu T; Zhang Y; Kerekes AD; Tagat JR; Doll RJ; Xiao Y; Esposite S; Hruza A; Belanger DB; Voss M; Rainka MP; Basso A; Liu M; Liang L; Sui N; Prelusky D; Rindgen D; Zhang L Bioorg Med Chem Lett; 2018 May; 28(8):1397-1403. PubMed ID: 29545102 [TBL] [Abstract][Full Text] [Related]
13. 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology. Beaufils F; Cmiljanovic N; Cmiljanovic V; Bohnacker T; Melone A; Marone R; Jackson E; Zhang X; Sele A; Borsari C; Mestan J; Hebeisen P; Hillmann P; Giese B; Zvelebil M; Fabbro D; Williams RL; Rageot D; Wymann MP J Med Chem; 2017 Sep; 60(17):7524-7538. PubMed ID: 28829592 [TBL] [Abstract][Full Text] [Related]
14. Discovery and optimization of a series of 2-aminothiazole-oxazoles as potent phosphoinositide 3-kinase γ inhibitors. Oka Y; Yabuuchi T; Fujii Y; Ohtake H; Wakahara S; Matsumoto K; Endo M; Tamura Y; Sekiguchi Y Bioorg Med Chem Lett; 2012 Dec; 22(24):7534-8. PubMed ID: 23122859 [TBL] [Abstract][Full Text] [Related]
15. Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors. Jin M; Wang J; Kleinberg A; Kadalbajoo M; Siu KW; Cooke A; Bittner MA; Yao Y; Thelemann A; Ji Q; Bhagwat S; Mulvihill KM; Rechka JA; Pachter JA; Crew AP; Epstein D; Mulvihill MJ Bioorg Med Chem Lett; 2013 Feb; 23(4):979-84. PubMed ID: 23317569 [TBL] [Abstract][Full Text] [Related]
16. Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors. Liang J; van Abbema A; Balazs M; Barrett K; Berezhkovsky L; Blair W; Chang C; Delarosa D; DeVoss J; Driscoll J; Eigenbrot C; Ghilardi N; Gibbons P; Halladay J; Johnson A; Kohli PB; Lai Y; Liu Y; Lyssikatos J; Mantik P; Menghrajani K; Murray J; Peng I; Sambrone A; Shia S; Shin Y; Smith J; Sohn S; Tsui V; Ultsch M; Wu LC; Xiao Y; Yang W; Young J; Zhang B; Zhu BY; Magnuson S J Med Chem; 2013 Jun; 56(11):4521-36. PubMed ID: 23668484 [TBL] [Abstract][Full Text] [Related]
17. Discovery of Potent Antiallergic Agents Based on an Xie Z; Xiang C; Li X; Fan C; Chen T; Liu M; Ma Y; Bai F; Tang W; Hu Y J Med Chem; 2021 Sep; 64(18):13588-13603. PubMed ID: 34476950 [TBL] [Abstract][Full Text] [Related]
18. Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. Mortensen DS; Sapienza J; Lee BG; Perrin-Ninkovic SM; Harris R; Shevlin G; Parnes JS; Whitefield B; Hickman M; Khambatta G; Bisonette RR; Peng S; Gamez JC; Leisten J; Narla RK; Fultz KE; Sankar S Bioorg Med Chem Lett; 2013 Mar; 23(6):1588-91. PubMed ID: 23414803 [TBL] [Abstract][Full Text] [Related]